![Wim Vermeulen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Roland Kanaar | M | - |
DNage BV
![]() DNage BV Miscellaneous Commercial ServicesCommercial Services DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH). The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders. DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands. | 8 jaar |
Jan-Kees de Jager | M | 55 |
Erasmus University Rotterdam
| 6 jaar |
Rein Strijker | M | 67 |
DNage BV
![]() DNage BV Miscellaneous Commercial ServicesCommercial Services DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH). The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders. DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands. | 8 jaar |
Gijsbertus T. J. van der Horst | M | - |
DNage BV
![]() DNage BV Miscellaneous Commercial ServicesCommercial Services DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH). The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders. DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands. | 8 jaar |
Sebastiaan Vaessen | M | - |
Erasmus University Rotterdam
| 6 jaar |
Edwin H. O. M. Bouwman | M | 57 |
Erasmus University Rotterdam
| 7 jaar |
Jan Hoeijmakers | M | - |
DNage BV
![]() DNage BV Miscellaneous Commercial ServicesCommercial Services DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH). The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders. DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands. | 8 jaar |
Rob Oudman | M | - |
Erasmus University Rotterdam
| 3 jaar |
Boudewijn Clemens Wentink | M | 55 |
Erasmus University Rotterdam
| 4 jaar |
Wilhelmus Simon Petrus Fortuijn | M | 76 |
Erasmus University Rotterdam
| 4 jaar |
Marianne Thieme | F | 52 |
Erasmus University Rotterdam
| 3 jaar |
Daan M. van Vlaardingen | M | - |
Erasmus University Rotterdam
| 6 jaar |
Mark P. Rutten | M | 49 |
Erasmus University Rotterdam
| 1 jaar |
Andrey Burlinov | M | 52 |
Erasmus University Rotterdam
| 2 jaar |
Daniel Wagener | M | - |
Erasmus University Rotterdam
| 6 jaar |
Robert Karreman | M | - |
Erasmus University Rotterdam
| 3 jaar |
Helen Tveitan-de Jong | F | 56 |
Erasmus University Rotterdam
| 4 jaar |
Hans van Seters | M | - |
Erasmus University Rotterdam
| 6 jaar |
Ziv Gil | M | 60 |
Erasmus University Rotterdam
| 2 jaar |
Johannes Hermanus de Wit | M | 62 |
Erasmus University Rotterdam
| 2 jaar |
Harry Elsinga | M | 59 |
Erasmus University Rotterdam
| 1 jaar |
Vincent Gerritsen | M | - |
Erasmus University Rotterdam
| 4 jaar |
Geert-Jan Schipper | M | 59 |
Erasmus University Rotterdam
| 4 jaar |
Nathalie Slechte | F | 56 |
Erasmus University Rotterdam
| 1 jaar |
Coen Van Oostrom | M | - |
Erasmus University Rotterdam
| 6 jaar |
Gideon Tilburgs | M | - |
Erasmus University Rotterdam
| 8 jaar |
Marion Hoogendijk | F | - |
Erasmus University Rotterdam
| 3 jaar |
Roland Toppen | M | - |
Erasmus University Rotterdam
| 6 jaar |
Choy van der Hooft-Cheong | M | 53 |
Erasmus University Rotterdam
| 1 jaar |
Pram Kurniawan | M | - |
Erasmus University Rotterdam
| 2 jaar |
Leo de Haan | M | - |
Erasmus University Rotterdam
| 3 jaar |
Maarten Smits | M | - |
Erasmus University Rotterdam
| 6 jaar |
Mariken Tannemaat | F | 52 |
Erasmus University Rotterdam
| 2 jaar |
geoff tomlinson | M | - |
Erasmus University Rotterdam
| 1 jaar |
Hubertus J. M. Vrijhoef | M | - |
Erasmus University Rotterdam
| 1 jaar |
Gérard van Spaendonck | M | 53 |
Erasmus University Rotterdam
| 7 jaar |
Arthur Alphons Johannes Hopstaken | M | - |
Erasmus University Rotterdam
| 4 jaar |
Ronald van Loon | M | - |
Erasmus University Rotterdam
| 6 jaar |
Sjoerd Mostert | M | - |
Erasmus University Rotterdam
| 5 jaar |
Tjarko Hektor | M | - |
Erasmus University Rotterdam
| 7 jaar |
Turan Erol | M | 63 |
Erasmus University Rotterdam
| 3 jaar |
David Knibbe | M | 53 |
Erasmus University Rotterdam
| 1 jaar |
Erik Esveld | M | - |
Erasmus University Rotterdam
| 4 jaar |
Dimitri Willems | M | - |
Erasmus University Rotterdam
| 4 jaar |
Maaike van der Schoot | F | - |
Erasmus University Rotterdam
| 6 jaar |
Paul Lageweg | M | 54 |
Erasmus University Rotterdam
| 6 jaar |
Harm M. M. Meijer | M | 49 |
Erasmus University Rotterdam
| 4 jaar |
René Kuijten | M | 60 |
DNage BV
![]() DNage BV Miscellaneous Commercial ServicesCommercial Services DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH). The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders. DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands. | - |
Robert Schier | M | - |
DNage BV
![]() DNage BV Miscellaneous Commercial ServicesCommercial Services DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH). The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders. DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands. | - |
Pieter Muntendam | M | 65 |
DNage BV
![]() DNage BV Miscellaneous Commercial ServicesCommercial Services DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH). The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders. DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands. | - |
Brent Wissink | M | 57 |
Erasmus University Rotterdam
| 4 jaar |
Gertjan Mulder | M | - |
Erasmus University Rotterdam
| 6 jaar |
Mark Wegter | M | 54 |
Erasmus University Rotterdam
| 1 jaar |
Jan Willem Gerritsen | M | - |
Erasmus University Rotterdam
| 4 jaar |
Jacob de Wit | M | 52 |
Erasmus University Rotterdam
| 5 jaar |
Maarten Friederich | M | - |
Erasmus University Rotterdam
| 4 jaar |
Ruulke Bagijn | F | - |
Erasmus University Rotterdam
| 3 jaar |
Sander van Vreumingen | M | 48 |
Erasmus University Rotterdam
| 7 jaar |
Erik M. van Mulligen | M | - |
Erasmus University Rotterdam
| 3 jaar |
Mark Jans | M | 54 |
Erasmus University Rotterdam
| 4 jaar |
Gerben C. M. Zondag | M | - |
DNage BV
![]() DNage BV Miscellaneous Commercial ServicesCommercial Services DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH). The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders. DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands. | 6 jaar |
Jeppe de Boer | M | - |
Erasmus University Rotterdam
| 4 jaar |
Johan Henrik Andresen | M | 63 |
Erasmus University Rotterdam
| 2 jaar |
Guus Hateboer | M | - |
DNage BV
![]() DNage BV Miscellaneous Commercial ServicesCommercial Services DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH). The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders. DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands. | - |
Ingrid van der Pluijm | M | - |
DNage BV
![]() DNage BV Miscellaneous Commercial ServicesCommercial Services DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH). The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders. DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands. | - |
Theo Berkvens | M | - |
DNage BV
![]() DNage BV Miscellaneous Commercial ServicesCommercial Services DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH). The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders. DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands. | - |
Lia P. M. Dam | M | - |
DNage BV
![]() DNage BV Miscellaneous Commercial ServicesCommercial Services DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH). The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders. DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands. | - |
Caspar Antonius Berendsen | M | 48 |
Erasmus University Rotterdam
| 4 jaar |
Marcel van Duin | M | - |
DNage BV
![]() DNage BV Miscellaneous Commercial ServicesCommercial Services DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH). The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders. DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands. | - |
Suzanna Maria Swarte | F | 56 |
Erasmus University Rotterdam
| 1 jaar |
Rene M. Lipsch | M | - |
Erasmus University Rotterdam
| 6 jaar |
Bram Grimmelt | M | - |
Erasmus University Rotterdam
| 6 jaar |
Henry Makansi | M | - |
Erasmus University Rotterdam
| 5 jaar |
Paul J. Vrancken | M | - |
Erasmus University Rotterdam
| 5 jaar |
Leni M. T. Boeren | F | 60 |
Erasmus University Rotterdam
| 4 jaar |
Paul van der Maas | M | - |
DNage BV
![]() DNage BV Miscellaneous Commercial ServicesCommercial Services DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH). The Company's main scientific founder Prof J. Hoeijmakers is a world-renowned scientist working on DNA repair and genome stability. His team was the first to establish an explicit connection between DNA damage (lack of repair) and the process of ageing, a scientific breakthrough. DNage has acquired exclusive access to this technology and now focuses on developing therapies to reduce the effects of ageing, leveraging the unique technologies developed by its founders. DNage has matured from an early stage technology company into a drug development company with ongoing clinical trials and several research programs. It has been acquired by Pharming Group NV in October 2006 and is currently involved in a financing round whereby Pharming will reduce its ownership to a non-controlling stake. The team of the company consists of approximately 15 people. DNage has laboratory facilities and offices in Rotterdam and Leiden, The Netherlands. | - |
Stephan Koen | M | - |
Erasmus University Rotterdam
| 4 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Nederland | 77 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Wim Vermeulen
- Persoonlijk netwerk